What is AggreDyne?
AggreDyne is a medical diagnostic company dedicated to advancing patient care through the development of sophisticated diagnostic tools. Its primary offering, the AggreGuide A-100, utilizes proprietary light scattering technology to provide a straightforward and dependable method for assessing platelet function. The company's target market includes hospital laboratories, physician office laboratories across various specialties, and larger regional reference laboratories. Established in 2011 and based in Houston, Texas, AggreDyne's diagnostic solutions have received FDA clearance and CE marking, validating their efficacy and market readiness.
How much funding has AggreDyne raised?
AggreDyne has raised a total of $102K across 1 funding round:
Debt
$102K
Debt (2021): $102K with participation from PPP
What's next for AggreDyne?
The substantial capital infusion, characterized as a large-scale late-stage funding, positions AggreDyne for significant expansion and market penetration. This strategic investment is likely to fuel further research and development, enhance manufacturing capabilities, and broaden the company's commercial reach. AggreDyne's focus on improving diagnostic accuracy and efficiency in critical healthcare settings suggests a trajectory aimed at capturing a larger share of the medical diagnostics market, potentially leading to further strategic partnerships or market consolidation.
See full AggreDyne company page
